evaluation of the effect of methylphenidate in children and adolescence with attention deficit hyperactivity disorder

evaluation of the effect of methylphenidate on prefronto-cerebellar neurometabolites in children and adolescence with attention deficit hyperactivity disorder: a proton magnetic resonance spectroscopy study

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201105049271N1

Enrollment

Registered

2020-11-25

Start date

2019-07-23

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder. Attention-deficit hyperactivity disorders

Interventions

Intervention 1: Intervention group: participants in this group have ADHD and received 8-weeks medication with methylphenidate three times a day (1mg per kg maximum dosage) that were began from 0.3-0.5

Eligibility

Sex/Gender

Male

Age

8 Years to 13 Years

Inclusion criteria

Inclusion criteria: Attention deficit hyperactivity disorder diagnosis without comorbidity Drug-naive at the age of 8 Normal IQ Boy age between 8 to 13 years old

Exclusion criteria

Exclusion criteria: Any medical and psychiatric disorder comorbidity Taking medication before the age of eight

Design outcomes

Primary

Measure	Time frame
Creatine: A neurometabolite wich is marker of energy metabolism. Timepoint: Before and after 8 week medication. Method of measurement: Magnetic resonance spectroscopy.;Choline: A neurometabolite wich is marker of membrane integrity. Timepoint: Before and after 8 week medication. Method of measurement: Magnetic resonance spectroscopy.;N-acetyl aspartate: A neurometabolite wich is marker of neural health. Timepoint: Before and after 8 week medication. Method of measurement: Magnetic resonance spectroscopy.;Mean latency in Rapid Visual Information Processing Test. Timepoint: Before and after 8 week medication. Method of measurement: CANTAB computerized test.;Total Hits in Rapid Visual Information Processing Test. Timepoint: Before and after 8 week medication. Method of measurement: CANTAB computerized test.;Total correct rejections in Rapid Visual Information Processing Test. Timepoint: Before and after 8 week medication. Method of measurement: CANTAB computerized test.;Strategy in Spatial Working Memory Test. Timepoint: Before and after 8 week medication. Method of measurement: CANTAB computerized test.;Between errors in Spatial Working Memory Test. Timepoint: Before and after 8 week medication. Method of measurement: CANTAB computerized test.;Within errors in Spatial Working Memory Test. Timepoint: Before and after 8 week medication. Method of measurement: CANTAB computerized test.;Visual vigilance in IVA test. Timepoint: Before and after 8 week medication. Method of measurement: IVA computerized test.;Auditory vigilance in IVA test. Timepoint: Before and after 8 week medication. Method of measurement: IVA computerized test.;Focus in IVA test (Visual). Timepoint: Before and after 8 week medication. Method of measurement: IVA computerized test.;Focus in IVA test (Auditory). Timepoint: Before and after 8 week medication. Method of measurement: IVA computerized test.;Speed in IVA test (Visual). Timepoint: Before and after 8 week medication. Method of measurement: IVA co	—

Measure

Time frame

Creatine: A neurometabolite wich is marker of energy metabolism. Timepoint: Before and after 8 week medication. Method of measurement: Magnetic resonance spectroscopy.;Choline: A neurometabolite wich is marker of membrane integrity. Timepoint: Before and after 8 week medication. Method of measurement: Magnetic resonance spectroscopy.;N-acetyl aspartate: A neurometabolite wich is marker of neural health. Timepoint: Before and after 8 week medication. Method of measurement: Magnetic resonance spectroscopy.;Mean latency in Rapid Visual Information Processing Test. Timepoint: Before and after 8 week medication. Method of measurement: CANTAB computerized test.;Total Hits in Rapid Visual Information Processing Test. Timepoint: Before and after 8 week medication. Method of measurement: CANTAB computerized test.;Total correct rejections in Rapid Visual Information Processing Test. Timepoint: Before and after 8 week medication. Method of measurement: CANTAB computerized test.;Strategy in Spatial Working Memory Test. Timepoint: Before and after 8 week medication. Method of measurement: CANTAB computerized test.;Between errors in Spatial Working Memory Test. Timepoint: Before and after 8 week medication. Method of measurement: CANTAB computerized test.;Within errors in Spatial Working Memory Test. Timepoint: Before and after 8 week medication. Method of measurement: CANTAB computerized test.;Visual vigilance in IVA test. Timepoint: Before and after 8 week medication. Method of measurement: IVA computerized test.;Auditory vigilance in IVA test. Timepoint: Before and after 8 week medication. Method of measurement: IVA computerized test.;Focus in IVA test (Visual). Timepoint: Before and after 8 week medication. Method of measurement: IVA computerized test.;Focus in IVA test (Auditory). Timepoint: Before and after 8 week medication. Method of measurement: IVA computerized test.;Speed in IVA test (Visual). Timepoint: Before and after 8 week medication. Method of measurement: IVA co

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Tehrani-Doost

Tehran University of Medical Sciences

tehranid@tums.ac.ir009855419151

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026